Osimertinib improves survival in cases of lung cancer metastasis, finds study has

The interesting findings revealed that-

1. After a median follow-up of 24 months (range, 3 to 28), a significant improvement in OS was detected (hazard ratio [HR] 0.59, 95% confidence interval [CI], 0.39–0.91; p = 0.0160; median, 13.7 months [95% CI, 11.1–14.8] for OSI vs 9.6 months [95% CI, 8.4–10.2] for AFA).
2. The median duration of PFS was significantly longer with OSI than with AFA (HR 0.62; 95% CI, 0.41–0.91; p = 0.014; median, 4.5 months [95% CI, 3.5–5.7] vs 3.9 months [95% CI, 3.1–4.8]).
3. The proportion of grade 3 or higher adverse events (AEs) was lower with OSI (22.4%) than with AFA (39.4%).

Therefore, the authors concluded that "noteworthy survival superiority of OSI over AFA was observed in patients with T790M-positive NSCLC and multiple CNS metastases after failure of initial EGFR-TKI treatment."

AFA is a broad HER-family inhibitor, whereas OSI is a highly specific EGFR-inhibitor directed towards the sensitizing mutations and a potent inhibitor of the T790M mutation. The latter is probably most important in this resistance setting, along with the better CNS-penetrance, they further added.